May 29 (Reuters) - Genvec Inc GNVC.O said its gene therapy product, TNFerade, increased survival of patients with esophageal cancer longer than comparable studies, sending its shares up 11 percent before the bell.
The company said long-term survival data from the mid-stage trial showed that following treatment with TNFerade and chemoradiation, the median overall survival of patients was 48.4 months. Literature review of comparable studies shows median survival ranging from 9.7 to 18.6 months, it added.
Shares of Genvec, which closed at $1.80 Wednesday on Nasdaq, were trading at $2.00 before the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Jarshad Kakkrakandy)
Our Standards: The Thomson Reuters Trust Principles.